Ruth Roberts on SOT Ballot

ApconiX is happy to announce that Ruth Roberts is on the SOT ballot for the position of Vice President-Elect.  As Secretary to SOT, Ruth was the first non-US based Council member and now hopes to be the first non-US based President! ‘It’s a great honour to be asked to stand for election to lead the [...]

By |2019-01-09T15:49:13+00:00January 9th, 2019|Events|Comments Off on Ruth Roberts on SOT Ballot

Alderley Park Companies Receive Bionow Awards

Drs Michael Morton and Richard Knight thoroughly enjoyed the Bionow 2018 Awards Dinner at the Mere Golf Resort & Spa, Cheshire on 29th November. The awards which recognise excellence, outstanding achievement and enterprise in a sector that is worth more than £13bn to the North’s economy, were sponsored by Manchester Science Partnerships, Alderley Park, Appleyard [...]

By |2018-12-16T19:10:57+00:00December 16th, 2018|Events|Comments Off on Alderley Park Companies Receive Bionow Awards

Highlight Article for Experimental Biology and Medicine

“Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration”, co-authored by Abigail L Walker, Syed Z Imam and  Ruth A Roberts, has been selected as a highlight article for Experimental Biology and Medicine’s 243:13 issue. As a result of this designation it will be open access for 90 days. Click here to access Abstract The [...]

By |2018-12-06T13:53:13+00:00December 7th, 2018|Publications|Comments Off on Highlight Article for Experimental Biology and Medicine

ApconiX at EUROTOX 2018

Dr Michael Morton, Professor Ruth Roberts, Dr Richard Knight and Dr Paul Duffy will be attending EUROTOX this September in Brussels. The theme for 2018 is “Toxicology Out of the Box” and reflects the federation’s willingness and enthusiasm to offer an innovative, forward-looking and imaginative scientific programme.  ‘"The theme for EUROTOX aligns perfectly with our [...]

By |2018-08-15T09:24:31+00:00August 15th, 2018|Toxicology, Events|Comments Off on ApconiX at EUROTOX 2018

Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Abstract: Neurotoxicity has been linked with exposure to a number of common drugs and chemicals, yet efficient, accurate, and minimally invasive methods to detect it are lacking. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid have great potential due to the relative ease of sampling but at present, data on [...]

By |2018-06-27T16:11:13+00:00February 28th, 2018|Toxicology, Publications|Comments Off on Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Attitude Toward Safety in Needs to Change

A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]

By |2018-06-27T16:32:28+00:00February 20th, 2018|Press|Comments Off on Attitude Toward Safety in Needs to Change

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

ApconiX New Year Message 2017!

As we get ready for a busy and exciting 2017, it’s a good time to reflect on ApconiX’s first full year in business and share some notable highlights. In 2016 we were joined by several additional preclinical experts including Dr Guy Healing, Dr Damian Deavall, Dr Jane Barber, Dr Mike O’Donovan and Dr Peter Ballard [...]

By |2018-06-06T14:51:39+00:00January 6th, 2017|Press|Comments Off on ApconiX New Year Message 2017!

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

Abstract Aberrant signaling by transforming growth factor-β (TGF-β) and its type I (ALK5) receptor has been implicated in a number of human diseases and this pathway is considered a potential target for therapeutic intervention. Transforming growth factor-β signaling via ALK5 plays a critical role during heart development, but the role of ALK5 in the adult [...]

By |2018-10-24T16:53:37+00:00August 27th, 2011|Toxicology, Publications|Comments Off on Induction of heart valve lesions by small-molecule ALK5 inhibitors.